Skip to main content
. 2021 Aug 26;22(17):9223. doi: 10.3390/ijms22179223

Figure 20.

Figure 20

(A,B) Crystal structures of hPPARχ LBD–rosiglitazone (full agonist) complex (PDB: 2PRG) and hPPARχ LBD–farglitazar (full agonist) complex (PDB: 1FM9). (C) The superimposed structures of hPPARχ LBD–rosiglitazone and hPPARχ LBD–farglitazar complexes. Both ligands are depicted as cylinder models, and Lys301 and Glu473 are highlighted as cylinder models in magenta (rosiglitazone complex) and cyan (farglitazar complex). The N-terminal AF2 region (H12 helix) is highlighted by a light red dotted box. (D) Chemical structures of rosiglitazone and farglitazar. (E) Zoomed view of the superimposed Lys301 of the hPPARχ LBD–rosiglitazone complex and hPPARχ LBD–farglitazar complex. Lys301 is highlighted as a cylinder model in magenta (rosiglitazone complex) or blue (farglitazar). (F) Zoomed view of the superimposed Glu473 of the hPPARχ LBD–rosiglitazone complex and hPPARχ LBD–farglitazar complex. Glu473 is highlighted as a cylinder model in magenta (rosiglitazone complex) or blue (farglitazar). Lys301 residues are highlighted as a green cylinder model.